Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Aquilus Pharmaceuticals Inc.
DescriptionDual inhibitor of matrix metalloproteinase-2 (MMP2) and MMP9
Molecular Target Matrix metalloproteinase 2 (MMP2) ; Matrix metalloproteinase 9 (MMP9)
Mechanism of ActionMatrix metalloproteinase inhibitor (MMPI)
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationNeuropathy
Indication DetailsTreat chronic neuropathic pain
Regulatory Designation
PartnerNeuroMax Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today